Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by chrispion Jan 19, 2021 12:48pm
189 Views
Post# 32327085

RE:RE:llike the run up, but...

RE:RE:llike the run up, but...even though no news precipitated the run-up.

Do you think SVA.v (Sernova) ran from .30 to .64 on news? nope, it ran from .64 to 2.40 on news.
The smart and lucky $ gets in before the news.
Where there is smoke there is fire.

As well, why does there always have to be news to substantiate a stock's run?
How about just the fact that we've been undervalued and underfollowed for such a long time (for various reasons) that certain investors are now waking up to that fact based on the news that the company has already released like:
  • that our transporter technology xB3 has shown to get more into the brain than Denali's,
  • or that a major pharma, Chiesi (in Italy), with $2B in revenues in 2019 paid us upfront monies ($3m USD) and huge milestone$ ($138m USD) to license our technology https://www.bioasis.us/bioasis-and-chiesi-group-announce-rare-diseases-strategic-alliance/
  • or that the CNS and blood-brain barrier technology marketplace is hot as evidenced by our competitor, Denali, having a mkt cap of about $13B CDN and Bioasis' was about $30m CDN.

<< Previous
Bullboard Posts
Next >>